VVOS Stock Overview
A medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Vivos Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.15 |
52 Week High | US$48.79 |
52 Week Low | US$1.91 |
Beta | 7.76 |
11 Month Change | 2.38% |
3 Month Change | -53.76% |
1 Year Change | -82.89% |
33 Year Change | -98.22% |
5 Year Change | n/a |
Change since IPO | -99.04% |
Recent News & Updates
Recent updates
It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Apr 25It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Feb 02Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)
Apr 18Vivos Therapeutics again delays Q2 2022 results
Aug 23Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada
Jun 29Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be
May 21Vivos Therapeutics: First Take After The Broad Market Sell-Off
Mar 06Vivos Therapeutics: Reimagining Sleep
Jul 30Vivos Therapeutics prices $24M follow-on offering
May 07Shareholder Returns
VVOS | US Healthcare | US Market | |
---|---|---|---|
7D | 0.9% | 0.4% | -0.3% |
1Y | -82.9% | 2.1% | 22.3% |
Return vs Industry: VVOS underperformed the US Healthcare industry which returned 3.5% over the past year.
Return vs Market: VVOS underperformed the US Market which returned 24.2% over the past year.
Price Volatility
VVOS volatility | |
---|---|
VVOS Average Weekly Movement | 15.5% |
Healthcare Industry Average Movement | 6.7% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.4% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: VVOS's share price has been volatile over the past 3 months.
Volatility Over Time: VVOS's weekly volatility has decreased from 120% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 119 | R. Huntsman | www.vivos.com |
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children.
Vivos Therapeutics, Inc. Fundamentals Summary
VVOS fundamental statistics | |
---|---|
Market cap | US$7.30m |
Earnings (TTM) | -US$15.64m |
Revenue (TTM) | US$13.36m |
0.5x
P/S Ratio-0.5x
P/E RatioIs VVOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VVOS income statement (TTM) | |
---|---|
Revenue | US$13.36m |
Cost of Revenue | US$5.49m |
Gross Profit | US$7.87m |
Other Expenses | US$23.51m |
Earnings | -US$15.64m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -4.61 |
Gross Margin | 58.90% |
Net Profit Margin | -117.06% |
Debt/Equity Ratio | 0% |
How did VVOS perform over the long term?
See historical performance and comparison